AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca recently completed a clinical study titled ‘A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD.’ The study aimed to assess the reliability of these diagnostic tests across patients with confirmed or suspected asthma or COPD, highlighting its importance in improving diagnostic accuracy for these conditions.
The study tested diagnostic interventions, specifically oscillometry and spirometry, on patients with suspected and confirmed cases of asthma and COPD. These tests are designed to measure lung function and help in diagnosing respiratory conditions.
This observational study followed a prospective case-only model. It was conducted across multiple centers, enrolling 800 patients in total, with an equal number of subjects for each condition category.
The study began on January 29, 2024, and was completed with the last update submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely dissemination of results.
The completion of this study could potentially boost AstraZeneca’s stock performance by reinforcing its commitment to advancing respiratory diagnostics. It may also impact investor sentiment positively, especially in comparison to competitors in the respiratory treatment market.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.